NGNE - Neurogene Inc.

9.03
1.690   18.715%

Share volume: 541,277
Last Updated: 04-09-2025
Pharmaceutical Products/Pharmaceutical Preparations: 0.07%

PREVIOUS CLOSE
CHG
CHG%
$7.34
1.69
0.23%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
28%
Profitability 0%
Dept financing 31%
Liquidity 50%
Performance 50%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
14.81%
1 Month
-47.04%
3 Months
-53.88%
6 Months
-81.25%
1 Year
-76.68%
2 Year
-38.15%
Key data
Stock price
$9.03
P/E Ratio 
0.00
DAY RANGE
$7.03 - $9.38
EPS 
-$4.28
52 WEEK RANGE
$6.88 - $74.49
52 WEEK CHANGE
-$76.44
MARKET CAP 
401.583 M
YIELD 
N/A
SHARES OUTSTANDING 
12.994 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-09-2025
BETA 
3.71
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$529,204
AVERAGE 30 VOLUME 
$335,022
Company detail
CEO: Jonathan G. Drachman
Region: US
Website: neoleukin.com
Employees: 90
IPO year: 2023
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Neoleukin Therapeutics, Inc. develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma.

Recent news
loading